| Species |
Human |
| Protein Construction |
TROP2, His, Human (His27-Thr274)
Accession # P09758 |
His tag |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1 EU per μg by the LAL method. |
| Biological Activity |
Immobilized TROP2, His, Human (Cat.No.: Z03807) at 0.5 μg/ml can bind Anti-TROP-2 Antibody. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
28.9 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 40-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the lyophilized product remains stable up to 6 months at -20 °C or below as supplied from date of receipt.
-80°C for 3 months after reconstitution.
2-8°C for 2-7 days after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
| Target Background |
The protein Trop-2, encoded by the TACSTD2 gene, is involved in tumor progression. It is overexpressed in various solid cancers including colorectal, renal, lung, and breast cancers, as well as in rare and aggressive malignancies such as salivary duct, anaplastic thyroid, uterine/ovarian, and neuroendocrine prostate cancers. |
| Synonyms |
EGP1; EGP-1; TROP2; GA733-1; gp50; T16; TACSTD2; TROP-2; M1S1; TACD2 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
